摘要
目的观察孟鲁司特对6～14岁儿童轻中度哮喘急性发作的改善情况。方法将6～14岁支气管哮喘急性发作患儿96例随机分为治疗组和对照组。治疗组在初始治疗时口服一次5mg孟鲁司特钠咀嚼片,对照组在初始治疗时口服一次安慰剂,然后两组均按照哮喘急性发作的医院治疗流程进行治疗,两组分别在治疗前和治疗后4h评估临床症状体征总评分和峰流速占预计值百分比的变化。结果治疗组和对照组在治疗后4h临床症状体征总评分及峰流速占预计值百分比与治疗前比较均有改善(P<0.05)。而且治疗组在治疗后4h的临床症状体征总评分低于对照组,峰流速占预计值百分比高于对照组,经统计学分析,均有统计学差异(P<0.05)。结论对6～14岁轻中度哮喘急性发作的患儿,在按照哮喘急性发作的医院治疗流程进行治疗的基础上,在初始治疗时口服孟鲁司特可明显促进症状进一步缓解,从而提高疗效。
Objective To observe the clinical curative effect of Montelukast for 6-14 patients with acute attack of asthma with mild to moderate degree.Methods 6-14 patients with acute onset of bronchial asthma 96 cases were randomly divided into two groups：the treated group and the control group.The treated group in the initial treatment took once-5mg montelukast sodium chewable tablets for oral administration;the control group took a placebo for oral administration in the initial treatment.Then the two groups were treated according to the hospital treatment of acute attack of asthma processes.Two groups were evaluated in the clinical symptoms and signs of total score and the percentage of total estimated value of peak flow before treatment and in 4 hours after treatment.Results Compared with pre-treatment,the treated group and the control groups were improved in the clinical symptoms and signs of total score and the percentage of total estimated value of peak flow in 4 hours after treatment（P 0.05）.The treated group was lower in the clinical symptoms and signs of total score and higher in the percentage of total estimated value of peak flow than the control group,it was significantly different（P0.05）.Conclusion For the 6-14-year-old children with mild to moderate acute asthma attack,it may significantly promote further relieve symptoms and improve the curative effect by taking montelukast for oral administration in the initial treatment on the basis of traditional treatments.
出处
《当代医学》
2010年第18期97-98,共2页
Contemporary Medicine
关键词
哮喘
治疗
孟鲁司特
儿童
asthma
treatment
montelukast
children
